Fortunato Ciardiello. ESMO and Congress President

Size: px

Start display at page:

Download "Fortunato Ciardiello. ESMO and Congress President"

Hilda Cole
6 years ago
Views:

1 OPENING SESSION

2 Fortunato Ciardiello ESMO and Congress President 2

3 3

4 ONE DREAM 23,000 participants 4

5 ESMO: 42 YEARS OF EXCELLENCE

6 ESMO: a membercentric society 6

7 7

15 ESMO STAFF

16 Anton Berns EACR President 16

17 Prof. Dr. Anton Berns PhD EACR President Director Emeritus Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital Amsterdam, The Netherlands

18 About the EACR Established in 1968 Over 10,000 members in 101 countries 14 affiliated National Societies (ASEICA etc.)

19 Members stats *Information from the members survey January 2017

20 Complementarity with ESMO Cancer research is a two-way street: Bench < > Bedside. Increasingly information from clinical trials lead to new basic research questions. Interaction between scientists along this trajectory is key for accelerating progress. Fostering this interaction, learning each others language, and jointly formulating new research questions, is what we aspire to in the ESMO EACR partnership. We are working to the same goal: improving prevention, diagnosis, and treatment of cancer. By working together we will make progress faster.

21 21

22 Miguel Martín Jiménez ESMO 2017 Local Officer 22

23 ESMO 2017 LOCAL OFFICER ADDRESS Prof. Miguel Martín Jiménez ESMO 2017 Local Officer Madrid, 8 September 2017 esmo.org

24 SEOM (Spanish Society of Medical Oncology), which I have the honor of presiding, is a National Scientific society in close collaboration with ESMO SEOM has members Board-certificated Spanish Medical Oncologists are actually working in Spain 378 Spanish Oncologists are members of ESMO and this number is increasing each year 79 Medical Oncology Services are accredited for training residents in Medical Oncology in our country esmo.org

25 43 Spanish speakers in ESMO2017 ( 8% of total speakers) 150 Spanish abstracts accepted in ESMO2017 (5% of total abstracts) total attendees to ESMO2017 (1.300 are Spanish) 130 Origin countries of attendees to ESMO2017 esmo.org

26 26

27 esmo.org

Underground http://www.planometromadrid.

28 Underground Line 8-Estación Feria de Madrid Bus lines: Line 112-Feria de Madrid - Bº Aeropuerto. Line 122-Avda. de América-Feria de Madrid. Line 828-Universidad Autónoma-Alcobendas-Feria de Madrid.

29 WELCOME TO MADRID! 29

30 Alberto Sobrero ESMO Scientific Co-Chair 30

31 ESMO SCIENTIFIC ADDRESS Alberto Sobrero ESMO 2017 Scientific Co-Chair Madrid, 8 September

32 ESMO 2017 SCIENTIFIC ADDRESS Alberto Sobrero ESMO 2017 Scientific Co-Chair Madrid, 8 September

33 ESMO 2017 and Congress President Fortunato Ciardiello, Naples, Italy ESMO 2017 SCIENTIFIC STEERING COMMITTEE ESMO 2017 Scientific Committee Co-Chairs ESMO: Alberto Sobrero, Genoa, Italy EACR: Richard Marais, Manchester, UK ESMO 2017 Educational Chair Andrés Cervantes, Valencia, Spain ESMO 2017 Local Officer Miguel Martín Jiménez, Madrid, Spain ESMO 2017 Press Officer Solange Peters, Lausanne, Switzerland 33

34 ESMO 2017 SCIENTIFIC COMMITTEE TRACK CHAIRS Basic science: Anton Berns, Amsterdam, Netherlands and Christof von Kalle, Heidelberg, Germany; Breast cancer, early stage: Nadia Harbeck, Munich, Germany: Breast cancer, metastatic: Fabrice André, Villejuif, France; CNS tumours: Michael Weller, Zurich, Switzerland; Developmental therapeutics: Jan Schellens, Amsterdam, Netherlands; Gastrointestinal tumours, colorectal: Volker Heinemann, Munich, Germany; Gastrointestinal tumours, non-colorectal: Eric Van Cutsem, Leuven, Belgium; Genitourinary tumours, prostate: Johann de Bono, Sutton, UK; Genitourinary tumours, non-prostate: Bernard Escudier, Villejuif, France; Gynaecological cancers: Domenica Lorusso, Milan, Italy; Haematological malignancies: Mariano Provencio, Madrid, Spain; Head and neck cancer: Jean-Pascal Machiels, Brussels, Belgium; Immunotherapy of cancer: Inge Marie Svane, Herlev, Denmark; Melanoma and other skin tumours: Reinhard Dummer, Zurich, Switzerland; NETs and endocrine tumours: Michel Ducreux, Villejuif, France; Non-metastatic NSCLC and other thoracic malignancies: Pilar Garrido, Madrid, Spain NSCLC, metastatic: Rafal Dziadziuszko, Gdansk, Poland; Public health and health economics: Paolo G. Casali, Milan, Italy; Sarcoma: Jean-Yves Blay, Lyon, France; Supportive and palliative care: Matti Aapro, Genolier, Switzerland; Translational research: Charles Swanton, London, UK (ESMO) and Joan Seoane, Barcelona, Spain (EACR); ESMO Patient Advocacy Working Group: Bettina Ryll, Uppsala, Sweden; ESMO Young Oncologists Committee: Matthias Preusser, Vienna, Austria Representing approx. 280 Scientific Committee members across the 21 tracks incl. 40 Educational Committee members on behalf of the full ESMO Faculty 34

35 THE MOST EXCITING ESMO CONGRESS EVER Four full days of Congress Programme Up to twelve sessions in parallel Three Presidential sessions, one each on Saturday, Sunday and Monday, presenting 7 Late-Breaking Abstracts (LBA) and 3 important practice-changing non-lbas More than 520 invited speakers Programme content with high-quality content for all oncology professionals

36 Extended Young Oncologist programme including new Mentor sessions Three Keynote lectures Four full Award lectures NOT-TO-MISS! 56 Industry satellites, including 2 ESMO Colloquia Full Patient Advocacy track over 4 days 16 Joint Symposia and 13 ad-hoc Special interest sessions Full sessions across 21 tracks 36

37 CLINICAL TRIALS REPRESENTED Phase I 101 Phase I/II 39 Phase II 177 Phase II/III 4 Phase III 161

38 ESMO 2017: LATE-BREAKING ABSTRACTS NOT TO MISS LBA2_PR Osimertinib vs standard of care (SoC) EGFR-TKI as firstline therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA LBA7_PR BRIM8: A randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence LBA4_PR 236O_PR RANGE: A randomized, double-blind, placebo-controlled phase 3 study of docetaxel (DOC) with or without ramucirumab (RAM) in platinum-refractory advanced or metastatic urothelial carcinoma MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2- advanced breast cancer LBA6_PR LBA8_PR COMBI-AD: Adjuvant dabrafenib (D) plus trametinib (T) for resected stage III BRAF V600E/K mutant melanoma Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238) 928O_PR Neoadjuvant chemotherapy followed by surgery (NACTsurgery) versus concurrent cisplatin and radiation therapy (CTRT) in patients with stage IB2 to IIB squamous carcinoma of cervix: A randomized controlled trial (RCT) LBA5 CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mrcc), including IMDC risk and PD-L1 expression subgroups

39 SCIENTIFIC AND EDUCATIONAL PROGRAMME AT A GLANCE Abstract related, 51 Educational: 46 sessions 25% of programme Scientific: 146 sessions 75% of programme Non-abstract related, 95

ESMO 2017 EDUCATIONAL PROGRAMME 2 21 23 46 sessions 25% of programme

40 ESMO 2017 EDUCATIONAL PROGRAMME sessions 25% of programme Educational sessions 23 Challenge your expert 21 Clinical Practice Guidelines 2

Non-abstract related ESMO 2017 SCIENTIFIC PROGRAMME Non-abstract related 5 2 9 3 21 1 3 3 13 20 24 8 18 16 Keynote sessions,

sessions, 13 Controversy sessions, 5 Congress Highlights, 2 Patient Advocacy sessions, 9 146 sessions 75% of the programme

41 Non-abstract related ESMO 2017 SCIENTIFIC PROGRAMME Non-abstract related Keynote sessions, 3 Special Symposia, 21 Multidisciplinary patient cases, 18 Joint symposia, 16 Young Oncologists sessions, 8 Ad-hoc special sessions, 13 Controversy sessions, 5 Congress Highlights, 2 Patient Advocacy sessions, sessions 75% of the programme Presidential Symposia, 3 Proffered paper sessions, 24 Poster discussion sessions, 20 Combined PP/PD session, 1 Poster sessions, 3

ESMO 2017 ABSTRACT SUBMISSION 3,260 submitted, 1 736 accepted Regular abstracts: 1,681 Late-breaking abstracts: 55 82

42 ESMO 2017 ABSTRACT SUBMISSION 3,260 submitted, accepted Regular abstracts: 1,681 Late-breaking abstracts: Oral presentation, 82 Poster discussion, 202 Poster display, 1397 Oral presentation 37 Poster discussion 18

Friday, 12 incl 1 Colloquium Monday, 14 incl 1 Colloqium

43 SATELLITE SYMPOSIA / ESMO COLLOQUIA ESMO 2017 Madrid ESMO 2016 Copenhagen 55 slots 56 slots Monday, 14 incl 1 Colloquium Friday, 12 incl 1 Colloquium Monday, 14 incl 1 Colloqium Friday, 12 Saturday, 14 Saturday, 15 Sunday, 15 incl 1 Colloquium Saturday, 15

44 Thank you and have a great Congress experience!

45 Richard Marais EACR Scientific Co-Chair

46 EACR SCIENTIFIC ADDRESS Professor Richard Marais EACR Scientific Co-Chair Madrid, 8 September

47 47

48 48

49 49

50 TRANSLATIONAL RESEARCH 50

51 THANK YOU! 51

52 THANK YOU! Jean-Charles Soria Annals of Oncology Editor-in-Chief

53 ESMO AWARD 2017 to

54 Miguel Martín Jiménez President of the Spanish Society of Medical Oncology (SEOM) Professor of Medicine at the Complutense University, Madrid, Spain Head of the Medical Oncology Service at the Hospital General Universitario Gregorio Marañon, in Madrid, Spain ESMO Award

Auditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES

Auditorium. Title: Welcome and Introduction by the Chairs Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES 08-04-2017 12:45-13:00 Type: Educational session Title: Welcome and Introduction by the Chairs 1 2 1 2 Moderation: M. Pless, A. Cervantes ; Winterthur, CH, Valencia, ES 12:45-13:00 Welcome 13:00-13:15